Last reviewed · How we verify
Decitabine in combination with R-CHOP
Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while R-CHOP chemotherapy directly kills lymphoma cells through multiple mechanisms.
Decitabine inhibits DNA methyltransferase to reactivate silenced tumor suppressor genes, while R-CHOP chemotherapy directly kills lymphoma cells through multiple mechanisms. Used for Lymphoid malignancies (likely diffuse large B-cell lymphoma or other non-Hodgkin lymphomas).
At a glance
| Generic name | Decitabine in combination with R-CHOP |
|---|---|
| Sponsor | Second Affiliated Hospital of Nanchang University |
| Drug class | Hypomethylating agent combined with chemotherapy regimen |
| Target | DNA methyltransferase (decitabine component); CD20, topoisomerase II, microtubule dynamics (R-CHOP components) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
Decitabine is a hypomethylating agent that reverses aberrant DNA methylation in cancer cells, restoring expression of epigenetically silenced genes. R-CHOP is a standard chemotherapy regimen (rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone) that combines immunotherapy with cytotoxic chemotherapy. The combination aims to enhance anti-tumor efficacy in lymphoid malignancies by synergizing epigenetic reactivation with direct cytotoxic effects.
Approved indications
- Lymphoid malignancies (likely diffuse large B-cell lymphoma or other non-Hodgkin lymphomas)
Common side effects
- Myelosuppression
- Nausea and vomiting
- Infection
- Cardiotoxicity
- Peripheral neuropathy
Key clinical trials
- A Multicenter, Prospective, Randomized, Controlled Study of Decitabine in Combination With R-CHOP for Initial Treatment of EBV+ Diffuse Large B-cell Lymphoma (PHASE3)
- CD-RCHOP in ND DLBCL With a Combination of TP53 Mutation and Del(17p) (PHASE2)
- Dynamic CtDNA-guided Targeted Therapy in DLBCL (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: